Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
PPARG 5468 ETALOCIB CHEMBL329123 agonist ChemblInteractions
PPARG 5468 ALEGLITAZAR CHEMBL519504 agonist TdgClinicalTrial, ChemblInteractions, DrugBank 20653327, 10592235
PPARG 5468 TROGLITAZONE CHEMBL408 agonist GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, TTD 12475986, 11752352, 10214942, 10222233, 10097144, 10076568, 10200320
PPARG 5468 INDOMETHACIN CHEMBL6 agonist, activator GuideToPharmacologyInteractions, DrugBank 9013583, 12689521
PPARG 5468 ROSIGLITAZONE CHEMBL121 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 10871190, 10475242, 11752352, 10764590, 10548525, 10707565
PPARG 5468 CHEMBL86658 CHEMBL86658 DrugBank 10592235
PPARG 5468 CHEMBL200495 CHEMBL200495 DrugBank 10592235
PPARG 5468 RAGAGLITAZAR CHEMBL24038 agonist GuideToPharmacologyInteractions, DrugBank 10592235
PPARG 5468 CHEMBL375270 CHEMBL375270 antagonist GuideToPharmacologyInteractions, DrugBank 10592235
PPARG 5468 CHEMBL1210221 CHEMBL1210221 DrugBank 10592235
PPARG 5468 EDAGLITAZONE CHEMBL2111091 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL88496 CHEMBL88496 agonist GuideToPharmacologyInteractions
PPARG 5468 GW7845 CHEMBL106666 agonist GuideToPharmacologyInteractions
PPARG 5468 NETOGLITAZONE CHEMBL93747 agonist, modulator TTD, GuideToPharmacologyInteractions, ChemblInteractions
PPARG 5468 BARDOXOLONE CHEMBL1093059 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL181937 CHEMBL181937 agonist GuideToPharmacologyInteractions
PPARG 5468 BARDOXOLONE METHYL CHEMBL1762621 antagonist GuideToPharmacologyInteractions, ChemblInteractions
PPARG 5468 DICLOFENAC CHEMBL139 antagonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL510698 CHEMBL510698 antagonist GuideToPharmacologyInteractions
PPARG 5468 TREPROSTINIL CHEMBL1237119 TdgClinicalTrial, TEND
PPARG 5468 ORANTINIB CHEMBL274654 agonist TTD
PPARG 5468 ZOLEDRONIC ACID CHEMBL924 PharmGKB
PPARG 5468 MESALAMINE CHEMBL704 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 18544567, 16939423, 18077625, 15824083
PPARG 5468 DB959 CHEMBL3545176 agonist TdgClinicalTrial, ChemblInteractions
PPARG 5468 TELMISARTAN CHEMBL1017 partial agonist DrugBank 16938288, 15868121, 16154710, 18580862, 17691961, 19147680, 15617852
PPARG 5468 BEZAFIBRATE CHEMBL264374 agonist DrugBank 16168052
PPARG 5468 CHEMBL201880 CHEMBL201880 DrugBank
PPARG 5468 CHEMBL451721 CHEMBL451721 DrugBank 10592235
PPARG 5468 CHEMBL378160 CHEMBL378160 DrugBank 10592235
PPARG 5468 CHEMBL364748 CHEMBL364748 DrugBank 10592235
PPARG 5468 TIROTUNDIN CHEMBL464453 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL434063 CHEMBL434063 agonist GuideToPharmacologyInteractions
PPARG 5468 L-165461 CHEMBL279053 agonist GuideToPharmacologyInteractions
PPARG 5468 L-796449 CHEMBL278994 agonist GuideToPharmacologyInteractions
PPARG 5468 LINOLEIC ACID CHEMBL267476 agonist GuideToPharmacologyInteractions
PPARG 5468 LY-510929 CHEMBL77502 agonist GuideToPharmacologyInteractions
PPARG 5468 BEXAROTENE CHEMBL1023 antagonist GuideToPharmacologyInteractions
PPARG 5468 CELECOXIB CHEMBL118 PharmGKB
PPARG 5468 EFATUTAZONE CHEMBL3545280 agonist TALC
PPARG 5468 OLANZAPINE CHEMBL715 PharmGKB
PPARG 5468 Efatutazone hydrochloride CHEMBL3545279 agonist TdgClinicalTrial, ChemblInteractions
PPARG 5468 GW501516 CHEMBL38943 TdgClinicalTrial
PPARG 5468 GENISTEIN CHEMBL44 agonist TTD
PPARG 5468 IMIGLITAZAR CHEMBL592054 agonist ChemblInteractions
PPARG 5468 TESAGLITAZAR CHEMBL282686 agonist ChemblInteractions
PPARG 5468 ROSIGLITAZONE MALEATE CHEMBL843 agonist ChemblInteractions, TTD
PPARG 5468 MURAGLITAZAR CHEMBL186179 agonist TdgClinicalTrial, ChemblInteractions
PPARG 5468 BALSALAZIDE DISODIUM CHEMBL1200760 agonist ChemblInteractions, DrugBank 19708827, 18077625, 20151072, 16939423
PPARG 5468 PIOGLITAZONE CHEMBL595 agonist TdgClinicalTrial, GuideToPharmacologyInteractions, TEND, DrugBank, TTD 7768881, 15356026, 11752352, 8576907, 9568680, 20018750
PPARG 5468 REGLITAZAR CHEMBL293526 agonist GuideToPharmacologyInteractions, DrugBank
PPARG 5468 ELAFIBRANOR CHEMBL3707395 DrugBank
PPARG 5468 CHEMBL1230670 CHEMBL1230670 DrugBank 10592235
PPARG 5468 CHEMBL191275 CHEMBL191275 DrugBank 10592235
PPARG 5468 CHEMBL1204498 CHEMBL1204498 DrugBank 10592235
PPARG 5468 TAGITININ A CHEMBL518700 agonist GuideToPharmacologyInteractions
PPARG 5468 CIGLITAZONE CHEMBL7002 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL410478 CHEMBL410478 agonist GuideToPharmacologyInteractions
PPARG 5468 GSK-9578 CHEMBL278590 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL24458 CHEMBL24458 agonist GuideToPharmacologyInteractions
PPARG 5468 FARGLITAZAR CHEMBL107367 agonist GuideToPharmacologyInteractions, ChemblInteractions
PPARG 5468 CHEMBL149394 CHEMBL149394 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL179330 CHEMBL179330 agonist GuideToPharmacologyInteractions
PPARG 5468 RESVERATROL CHEMBL165 antagonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL146624 CHEMBL146624 TdgClinicalTrial
PPARG 5468 BALAGLITAZONE CHEMBL2103991 partial agonist ChemblInteractions
PPARG 5468 RIVOGLITAZONE CHEMBL2104753 agonist ChemblInteractions
PPARG 5468 BALSALAZID CHEMBL1201346 TdgClinicalTrial
PPARG 5468 NAVEGLITAZAR CHEMBL181954 agonist TdgClinicalTrial, ChemblInteractions
PPARG 5468 ARHALOFENATE CHEMBL2103824 modulator ChemblInteractions
PPARG 5468 OLSALAZINE SODIUM CHEMBL1201013 agonist ChemblInteractions
PPARG 5468 MK-0533 CHEMBL490029 modulator ChemblInteractions
PPARG 5468 ICOSAPENT ETHYL CHEMBL2095209 TdgClinicalTrial
PPARG 5468 AVE0847 CHEMBL3545295 agonist ChemblInteractions
PPARG 5468 PIOGLITAZONE HYDROCHLORIDE CHEMBL1715 agonist ChemblInteractions
PPARG 5468 INDEGLITAZAR CHEMBL1232583 agonist ChemblInteractions, DrugBank 10592235
PPARG 5468 ICOSAPENT CHEMBL460026 agonist DrugBank 17052999, 16702329, 17610002, 12055328, 11552681
PPARG 5468 SULFASALAZINE CHEMBL421 agonist TdgClinicalTrial, DrugBank 18544567, 16939423, 18077625, 15824083
PPARG 5468 INT131 CHEMBL1236924 modulator TdgClinicalTrial, ChemblInteractions, DrugBank
PPARG 5468 CLX-0921 CHEMBL3545240 agonist TdgClinicalTrial, ChemblInteractions, DrugBank
PPARG 5468 CHEMBL191060 CHEMBL191060 DrugBank 10592235
PPARG 5468 CHEMBL23296 CHEMBL23296 agonist GuideToPharmacologyInteractions
PPARG 5468 CHEMBL1946409 CHEMBL1946409 agonist GuideToPharmacologyInteractions
PPARG 5468 MBX-2044 CHEMBL3545020 modulator TdgClinicalTrial, ChemblInteractions
PPARG 5468 METAGLIDASEN CHEMBL451321 TdgClinicalTrial
PPARG 5468 SODELGLITAZAR CHEMBL2104984 agonist ChemblInteractions
PPARG 5468 OMS405 CHEMBL3545277 agonist ChemblInteractions
PPARG 5468 ATx08-001 CHEMBL3545278 modulator ChemblInteractions
PPARG 5468 NATEGLINIDE CHEMBL783 agonist DrugBank 17082235
PPARG 5468 MITIGLINIDE CHEMBL471498 agonist DrugBank 17082235
PPARG 5468 GLIPIZIDE CHEMBL1073 agonist DrugBank 17082235
PPARG 5468 REPAGLINIDE CHEMBL1272 agonist DrugBank 17082235

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
PPARG rs1801282 CG rosiglitazone efficacy yes The response rate to rosiglitazone treatment was lower in the Pro12Pro (CC) group vs. Pro12Ala (CG) variant group (43.72% versus 86.67%, P =0.002). The decrease in fasting plasma glucose level was significantly greater in subjects with the Ala12 allele than in those without the allele (50.6 -27.8mg/dL versus 24.3 -41.9 mg/dL, P=0.026). In addition, the decrease in hemoglobin A1c level was significantly greater in subjects with the Ala12 allele than in those without the allele (1.41% -1.47% versus 0.57% -1.16%, P =0 .015). Genotype CG is associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC. 16084854 981481521
PPARG rs1801282 CG pioglitazone efficacy yes Patients with the CG genotype showed significantly greater decreases in fasting plasma glucose levels and triglyceride levels after 3 months of pioglitazone treatment. However, changes in other biochemical measures were not significant. Genotype CG is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC. 23147557 1450814898